THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in **Hanx Biopharmaceuticals (Wuhan) Co., Ltd.** you should at once hand this circular, together with the enclosed form of proxy, to the purchaser(s) or the transferee(s) or to the bank, licensed securities dealer or other agent through whom the sale or transfer was effected for transmission to the purchaser(s) or the transferee(s).

Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
翰思艾泰生物醫藥科技（武漢）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3378)

PROPOSAL FOR GRANTING THE GENERAL MANDATE TO REPURCHASE H SHARES AND NOTICE OF EXTRAORDINARY GENERAL MEETING

The notice convening the EGM of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. to be held at 10:00 a.m. on Thursday, February 12, 2026 at the Company's conference room at 3/F, Building A8, Phase II of Bio-Innovation Park, No. 1 Jiufeng 1st Road, East Lake New Technology Development Zone, Wuhan City, Hubei Province, the PRC is set out on pages EGM-1 to EGM-3 of this circular. A form of proxy for use at the EGM is enclosed with this circular and published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.hanxbio.com) respectively.

Whether or not you intend to attend the EGM, you are required to complete the form of proxy in accordance with the instructions printed thereon and return it to the Company's H Share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, as soon as possible but in any event not less than 24 hours before the time appointed for holding the EGM (i.e. not later than 10:00 a.m. on Wednesday, February 11, 2026) or any adjournment thereof. Completion and return of the form of proxy shall not preclude you from attending and voting in person at the EGM or any adjournment thereof if you so wish.

Reference to dates and time in this circular are to Hong Kong dates and time. Where the context so permits or requires in this circular, words importing the singular number include the plural and vice versa and words importing the masculine gender include the feminine and neuter genders and vice versa.

January 27, 2026

CONTENTS

In this circular, the following expressions have the following meanings unless the context requires otherwise:

"Articles of Association"	the articles of association of the Company, as amended from time to time
"associates"	has the meaning ascribed thereto under the Listing Rules
"Board"	the board of Directors
"Caizhang Vision"	Caizhang Vision Limited, a company incorporated in the BVI on January 23, 2019
"CCASS"	the Central Clearing and Settlement System established and operated by the HKSCC
"Company"	Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (翰思艾泰生物醫藥科技(武漢)股份有限公司), a joint stock company incorporated in the PRC on December 19, 2014 whose shares are listed on the Stock Exchange (stock code: 3378)
"connected person(s)"	has the meaning ascribed thereto under the Listing Rules
"Controlling Shareholders"	collectively refers to the controlling shareholders of our Company, being CZ Biotechnology, Dr. Zhang, Ms. Luo Fang (the spouse of Dr. Zhang), Caizhang Vision, Hanx Biopharmaceuticals, HanxBio (BVI), Hanx Biopharmaceuticals (HK) and Wuhan Hanx
"CZ Biotechnology"	Cai Zhang Biotechnology (Hangzhou) Co., Ltd. (蔡張生物科技(杭州)有限責任公司), a company with limited liability established in the PRC on September 7, 2017
"Directors"	the directors of the Company
"Dr. Zhang"	Dr. Zhang Faming (張發明), the chairman of the Board, an executive Director and one of our Controlling Shareholders
"EGM"	the extraordinary general meeting of the Company to be held at the Company's conference room at 3/F, Building A8, Phase II of Bio-Innovation Park, No. 1 Jiufeng 1st Road, East Lake New Technology Development Zone, Wuhan City, Hubei Province, the PRC on Thursday, February 12, 2026 at 10:00 a.m., to consider and, if thought fit, to approve the resolution contained in the notice of the meeting which is set out on pages EGM-1 to EGM-3 of this circular, or any adjournment thereof

"H Share(s)"	the ordinary share(s) in the share capital of our Company with a nominal value of RMB0.1 each, which are traded in Hong Kong dollars and listed on the Stock Exchange
"Hanx Biopharmaceuticals"	HanX Biopharmaceuticals Limited, a company incorporated in the Cayman Islands on January 30, 2019
"Hanx Biopharmaceuticals (HK)"	Hanx Biopharmaceuticals (HK) Limited (翰思生物醫藥(香港)有限公司), a company incorporated in Hong Kong with limited liability on April 1, 2022
"HanxBio (BVI)"	HanXBio (BVI) Limited, a company incorporated in the BVI with limited liability on February 21, 2022
"HK$" or "Hong Kong dollar(s)"	Hong Kong dollar(s), the lawful currency of Hong Kong
"HKSCC"	Hong Kong Securities Clearing Company Limited, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Hong Kong Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Latest Practicable Date"	January 23, 2026, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained herein
"Listing Rules"	the Rules Governing the Listing of Securities on Main Board of the Stock Exchange as amended, supplemented or otherwise modified from time to time
"PRC" or "China"	the People's Republic of China, and for the purpose of this circular, excluding Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
"Repurchase Mandate"	a general mandate proposed to be granted to the Board at the EGM to repurchase H Shares of up to a maximum of 10% of the total number of H Shares (excluding any Treasury Shares) in issue as at the date of passing the relevant resolutions
"RMB"	Renminbi, the lawful currency of the PRC
"Share(s)"	ordinary shares in the share capital of the Company with a nominal value of RMB0.1 each

"Shareholder(s)"	the registered holder(s) of Shares
"Takeovers Code"	the Codes on Takeovers and Mergers and Share Buy-backs issued by the Securities and Futures Commission of Hong Kong (as amended from time to time)
"Treasury Shares"	has the meaning ascribed to it under the Listing Rules
"Wuhan Hanx"	Wuhan Hanx Tai Management Consulting Partnership (Limited Partnership)* (武漢市翰思泰管理諮詢合夥企業(有限合夥)), a limited partnership established in the PRC on June 3, 2024
"%"	per cent

Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
翰思艾泰生物醫藥科技（武漢）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3378)

Executive Directors:
Dr. Zhang Faming *(Chairman)*
Dr. Henry Qixiang Li
Mr. Liu Min

Non-executive Directors:
Dr. Li Jian
Ms. Xiao Jieyu

Independent Non-executive Directors:
Dr. Bi Honggang
Mr. Chen Qifeng
Mr. Wong Sai Hong
Dr. Zhang Qiongguang

Registered address:
Building A8, Phase II
Bio-Innovation Park
No. 1 Jiufeng 1st Road
East Lake New Technology Development Zone
Wuhan, Hubei
PRC

Principal place of business in Hong Kong:
3/F, Building 2W
Science Park Avenue
Hong Kong Science Park
Shatin
New Territories
Hong Kong

January 27, 2026

To the Shareholders

Dear Sir or Madam,

PROPOSAL FOR GRANTING THE GENERAL MANDATE TO REPURCHASE H SHARES AND NOTICE OF EXTRAORDINARY GENERAL MEETING

I. INTRODUCTION

The purpose of this circular is to provide you with information regarding the notice of the EGM and the resolution to be proposed at the EGM relating to proposal for granting the general mandate to repurchase H Shares.

II. PROPOSAL FOR GENERAL MANDATE TO REPURCHASE H SHARES

In order to maintain the value and Shareholders' rights of the Company and enable the Company to repurchase its Shares in a timely and flexible manner, a special resolution will be proposed at the EGM to approve the granting of the general mandate to repurchase H Shares granted to the Board, which is to repurchase H Shares on the Hong Kong Stock

Exchange, with a quantity not exceeding 10% of the issued H Shares (excluding any Treasury Shares) as at the date of passing the relevant resolution of the Repurchase Mandate. The Board is authorized to exercise all rights of the Company to repurchase H Shares in accordance with all applicable laws and regulations of the PRC government or securities regulatory authorities and the Hong Kong Stock Exchange during the Relevant Period (as defined in the notices of the EGM), and is authorized to make (including but not limited to) the following actions:

(i) determine the specific repurchase plan, including but not limited to the repurchase price, number of H Shares to be repurchased, repurchase timing and repurchase period, etc.;

(ii) open stock accounts and handle the relevant procedures for the repurchase funds, etc.;

(iii) determine the specific use of the repurchased H Shares in accordance with the actual situation of the Company and to adjust or change such use as permitted by the relevant laws and regulations;

(iv) based on market conditions and the capital management needs of the Group at the time of repurchase, decide to cancel such repurchased H Shares or hold such repurchased H Shares as Treasury Shares;

(v) if it is decided to cancel the repurchased H Shares, in accordance with the provisions of the Articles of Association, the cancellation procedures for repurchased Shares shall be carried out to reduce the registered capital of the Company, and the Articles of Association shall be amended as it deems appropriate and necessary to reflect the reduction in the registered capital of the Company; and

(vi) take any other necessary actions and complete any necessary procedures to repurchase such Shares under the Repurchase Mandate.

According to the Repurchase Mandate, the total number of H Shares repurchased during the Relevant Period (as defined in the notice of the EGM) shall not exceed 10% of the total number of H Shares issued by the Company (excluding any Treasury Shares) as at the date of passing the relevant resolution of the Repurchase Mandate by the Shareholders.

The Board must comply with the Listing Rules (as amended from time to time), relevant laws and regulations in the PRC, the Articles of Association, and obtain approval from all regulatory authorities (if applicable) before exercising the Repurchase Mandate.

The Repurchase Mandate can only be implemented after the EGM has passed the resolution for the Repurchase Mandate. If approved, the Repurchase Mandate will expire on the earliest of the following dates:

(i) the conclusion of the next annual general meeting of the Company after the passing of the resolution for Repurchase Mandate at the EGM;

(ii) the date on which the next annual general meeting of the Company is required to be held by the Articles of Association or other applicable laws; or

(iii) the date on which the Shareholders pass a special resolution at the Shareholders' meeting to revoke or amend the authorization granted to the Board as stated in the resolution for Repurchase Mandate.

The Repurchase Mandate complies with the Listing Rules, the Articles of Association and applicable laws, rules and regulations of the PRC government and regulatory authorities. The resolution for the Repurchase Mandate is set out in the EGM notice attached to this circular.

Appendix I to this circular is an explanatory statement containing information regarding the Repurchase Mandate.

The relevant proposal will be presented as a special resolution at the EGM for review and approval by the Shareholders.

III. CLOSURE OF THE REGISTER OF MEMBERS

In order to determine the Shareholders who are entitled to attend the EGM, the register of members of the Company will be closed from February 9, 2026 to February 12, 2026, both days inclusive, during which no transfer of Shares will be registered.

To be entitled to attend and vote at the EGM, Shareholders whose transfer of Shares have not been registered must lodge all transfer instruments accompanied by the relevant share certificates with the Company's H Shares registrar and transfer office, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration at or before 4:30 p.m. on February 6, 2026 (Hong Kong time).

IV. VOTING BY POLL

Pursuant to Rule 13.39(4) of the Listing Rules, any vote of Shareholders at a general meeting must be taken by poll. Accordingly, the resolutions to be proposed at the EGM will be voted by poll. The poll results will be published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.hanxbio.com) upon the conclusion of the EGM.

To the best of the knowledge, information and belief of the Directors, having made all reasonable enquiries, no Shareholder is required to abstain from voting in respect of the resolutions proposed at the EGM pursuant to the Listing Rules and/or the Articles of Association.

V. RECOMMENDATIONS

The Directors consider that the proposed resolutions in respect of the proposals for the proposal for granting the general mandate to repurchase H Shares is fair and reasonable and in the best interests of the Company and its Shareholders as a whole. Accordingly, the Board recommends the Shareholders to vote in favour of all the above resolution as set out in the notice of the EGM.

VI. RESPONSIBILITY STATEMENT

This circular includes particulars given in compliance with the Listing Rules for the purpose of giving information with respect to the Company. The information contained herein relating to the Company has been provided by the Directors, who collectively and individually accept full responsibility for the accuracy of the information contained in this circular and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts not contained in this circular the omission of which would make any statement herein misleading insofar as it relates to the Company.

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

VII. ADDITIONAL INFORMATION

Your attention is also drawn to the additional information set out in the appendices to this circular.

Yours faithfully,
For and on behalf of the Board
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Dr. ZHANG Faming
Chairman and Executive Director

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.

The following is the explanatory statement which is required to be sent to you under the Listing Rules in connection with the proposed Repurchase Mandate:

I. REASONS FOR REPURCHASE OF H SHARES

The Directors believe that seeking authorization from Shareholders to repurchase H Shares by the Company in the market is in the best interests of the Company and its Shareholders. The repurchase of Shares may result in an increase in the net asset value and/or earnings per share of the Company, subject to market conditions and funding arrangements at the time. On the other hand, the Shares repurchased by the Company and held as Treasury Shares may be resold in the market at market price to raise funds for the Company, or transferred or used for other purposes, subject to compliance with the Listing Rules, the Articles of Association, and applicable laws, regulations, and rules in the PRC. The Company will only repurchase Shares when the Directors believe that it is beneficial for the Company and its Shareholders.

II. REGISTERED CAPITAL

As at the Latest Practicable Date, the number of total issued shares of the Company was 136,218,830 H Shares.

III. EXERCISE OF THE REPURCHASE MANDATE

Subject to the passing of the relevant special resolution approving the grant of the Repurchase Mandate to the Directors at the EGM, the Directors will be granted the Repurchase Mandate until the end of the Relevant Period (as defined in the notices of the EGM and the Class Meetings). In addition, the exercise of the Repurchase Mandate is subject to the approvals of the relevant PRC regulatory authorities as required by the laws, rules and regulations of the PRC being obtained (if applicable), and is also subject to the provisions of the Articles of Association.

Neither this explanatory statement nor the Repurchase Mandate has any unusual features.

As at the Latest Practicable Date, assuming the Repurchase Mandate is only required to be approved at the EGM, the exercise in full of the Repurchase Mandate would result in up to 13,621,883 H Shares (assuming there is no issue of additional H Shares from the Latest Practicable Date up to the date of the EGM) being repurchased by the Company during the Relevant Period (as defined in the notices of the EGM and the Class Meetings).

IV. FUNDING OF REPURCHASES OF H SHARES

In repurchasing its H Shares, the Company intends to apply funds from the Company's internal resources (which may include surplus funds and retained profits) legally available for such purpose in accordance with the Articles of Association and the applicable laws, rules and regulations of the PRC.

Based on the financial position disclosed in the recently published audited accounts for the eight months ended August 31, 2025 of the Company, the Directors consider that there will not be any material adverse impact on the working capital or gearing position of the Company in the event that the Repurchase Mandate is to be exercised in full at any time during the Relevant Period (as defined in the notices of the EGM). The number of H Shares to be repurchased on any occasion and the price and other terms upon which the same are repurchased will be decided by the Directors at the relevant time having regarded to the circumstances then prevailing and in the best interests of the Company.

V. STATUS OF REPURCHASED H SHARES

The repurchased H Shares by the Company may be cancelled or held as the Treasury Shares, subject to market conditions and the capital management needs of the Group during the Relevant Period (as defined in the notice of the EGM).

For any Treasure Shares of the Company stored in the CCASS for resale on the Hong Kong Stock Exchange, the Company shall take appropriate measures necessary to ensure that such Treasury Shares are appropriately identified and segregated.

VI. PRICES OF H SHARES

The highest and lowest prices at which the H Shares have been traded on the Stock Exchange during the period from December 23, 2025 (the date of listing of the H Shares on the Stock Exchange) to the Latest Practicable Date were as follows:

	H Shares Prices	
	Highest	**Lowest**
	HK$	*HK$*
2025		
December (from December 23, 2025)	29.48	13.48
2026		
January (up to the Latest Practicable Date)	17.58	15.29

VII. GENERAL INFORMATION

(a) None of the Directors nor, to the best of their knowledge and having made all reasonable enquiries, any of their associates, have any present intention to sell any H Shares to the Company or any of its subsidiaries under the Repurchase Mandate if the same is approved by the Shareholders of the Company.

(b) The Directors will exercise the power of the Company in accordance with the Listing Rules, the Articles of Association and the applicable laws of the PRC to repurchase the H Shares pursuant to the Repurchase Mandate.

(c) No core connected person (as defined in the Listing Rules) of the Company has notified the Company that he/she has a present intention to sell H Shares to the Company or its subsidiaries, or has undertaken not to do so, if the Repurchase Mandate is granted and is exercised.

VIII. TAKEOVERS CODE

If on the exercise of the power to repurchase H Shares pursuant to the Repurchase Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition for the purpose of Rule 32 of the Takeovers Code. As a result, a Shareholder or a group of Shareholders acting in concert could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rules 26 and 32 of the Takeovers Code.

As at the Latest Practicable Date, the group of Controlling Shareholders controls or is entitled to control the voting rights of 76,138,710 H Shares of the Company, which account for approximately 55.89% of the Company's total issued share capital. If the general mandate to repurchase H Shares is fully exercised and assuming that no further issuance or repurchase of H Shares is made prior to such full exercise, the proportion of the interest of the voting rights held by the group of Controlling Shareholders in the Company to the total share capital of the Company will therefore increase to approximately 62.10% (if it does not participate in such repurchase). Such increase would not give rise to a general offer obligation under the Takeovers Code. The Directors do not have present intention to exercise the Repurchase Mandate to such an extent as would give rise to such an obligation.

Assuming that there is no issue of H Shares between the Latest Practicable Date and the date of a repurchase of H Shares, an exercise of the Repurchase Mandate whether in whole or in part will not result in less than the relevant prescribed minimum percentage of the Shares of the Company being held by the public as required by the Hong Kong Stock Exchange. The Directors have no intention to exercise the Repurchase Mandate to an extent which may result in a public shareholding of less than such minimum percentage.

At the Latest Practicable Date, save as disclosed above, the Directors are not aware of any consequences that may arise under the Takeovers Code and/or any similar applicable laws of which the Directors are aware, as a result of any repurchase of Shares made under the proposed resolution.

IX. SHARE REPURCHASES MADE BY THE COMPANY

The Company has not repurchased any of its H Shares during the six months' period preceding the Latest Practicable Date.

Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
翰思艾泰生物醫藥科技（武漢）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3378)

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the "**EGM**") of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the "**Company**") will be held at the Company's conference room at 3/F, Building A8, Phase II of Bio-Innovation Park, No. 1 Jiufeng 1st Road, East Lake New Technology Development Zone, Wuhan City, Hubei Province, the PRC on Thursday, February 12 2026 at 10:00 a.m. (the "**Meeting**") for the purposes of considering and, if thought fit, passing the following matter.

SPECIAL RESOLUTION

To consider and, if thought fit, approve:

1. **Proposal for granting the general mandate to repurchase H Shares**

   "THAT:

   (a) According to all applicable laws and regulations of the PRC government or securities regulatory authorities, as well as the Hong Kong Stock Exchange, repurchase H Shares on terms deemed appropriate, not exceeding 10% of the total number of issued H Shares (excluding any Treasury Shares) as of the date of this resolution;

   (b) The Board is authorized to make (including but not limited to) the following during the Relevant Period:

      (i) determine the specific repurchase plan, including but not limited to the repurchase price, number of Shares to be repurchased, repurchase timing and repurchase period, etc.;

      (ii) open stock accounts and handle the relevant procedures for the repurchase funds, etc.;

      (iii) determine the specific use of the repurchased H Shares in accordance with the actual situation of the Company and to adjust or change such use as permitted by the relevant laws and regulations;

      (iv) based on market conditions and the capital management needs of the Group at the time of repurchase, decide to cancel such repurchased H Shares or hold such repurchased H Shares as Treasury Shares;

(v) if it is decided to cancel the repurchased H Shares, in accordance with the provisions of the Articles of Association, the cancellation procedures for repurchased shares shall be carried out to reduce the registered capital of the Company, and the Articles of Association shall be amended as it deems appropriate and necessary to reflect the reduction of the registered capital of the Company; and

(vi) take any other necessary actions and complete any necessary procedures to repurchase such shares in accordance with paragraph (a) of this special resolution.

(c) For the purpose of this special resolution, "Relevant Period" refers to the period from the date of its adoption to the earliest of the following:

(i) at the conclusion of the next annual general meeting of the Company after the passing of this resolution;

(ii) the date on which the next annual general meeting of the Company is required to be held by the Articles of Association or other applicable laws; or

(iii) the date on which the Shareholders pass a special resolution at the Shareholders' meeting to revoke or amend the authorization granted to the Board as stated in this resolution."

Yours faithfully,
For and on behalf of the Board
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Dr. ZHANG Faming
Chairman and Executive Director

Hong Kong, January 27, 2026

As at the date of this notice, the Board comprises (i) Dr. Zhang Faming, Dr. Henry Qixiang Li and Mr. Liu Min as executive Directors; (ii) Dr. Li Jian and Ms. Xiao Jieyu as non-executive Directors; and (iii) Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung and Dr. Zhang Qiongguang as independent non-executive Directors.

Notes:

1. Unless otherwise indicated, capitalized terms used herein shall have the same meaning as those defined in the circular of the Company dated January 27, 2026.

2. For details of the proposal for granting the general mandate to repurchase H Shares, please refer to the accompanying circular.

3. In order to determine the Shareholders who are entitled to attend the EGM, the register of members of the Company will be closed from February 9, 2026 to February 12, 2026, both days inclusive, during which no transfer of Shares will be registered.

   To be entitled to attend and vote at the EGM, Shareholders whose transfer of Shares have not been registered must lodge all transfer instruments accompanied by the relevant share certificates with the Company's H Shares registrar and transfer office, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration at or before 4:30 p.m. on February 6, 2026 (Hong Kong time).

4. Shareholders of the Company whose names appear on the register of members of the Company on February 12, 2026 will be entitled to attend and vote at the EGM or any adjourned meetings.

5. If a Shareholder appoints more than one proxy to attend the meeting, its proxy can only vote by poll.

6. Shareholders who have the right to attend and vote at the EGM are entitled to appoint one or more proxies (whether or not a Shareholder) to attend and vote on his/her/its behalf. For those Shareholders who appoint more than one proxy, such proxies can only exercise their voting rights by way of poll. Shareholders who intend to appoint one or more proxies should first read the accompanying circular.

7. If a proxy is appointed to attend the EGM on behalf of a Shareholder, the proxy must produce proof of identity and the authorisation instrument with the date of issue and duly signed by the proxy or its legal personal representative, and in the case of legal representatives of legal person Shareholders, such legal representatives must produce proof of identity and effective document to identify its identity as legal representative. If a legal person Shareholder appoints a company representative other than its legal representative to attend the EGM, such representative must produce proof of identity and the authorisation instrument bearing the company chop of the legal person Shareholder and duly authorised by its legal representative.

8. If the proxy form is signed by a person under a power of attorney or other authority, the power of attorney or other authority must be notarially certified. In order to be valid, the notarially certified copy of such power of attorney or other authority under which it is signed together with the proxy form must be deposited not less than 24 hours before the time for holding the EGM at the H Shares registrar of the Company, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong.

9. The EGM is expected to be held for less than half a day. Shareholders and their proxies who attend the meeting shall arrange for their own transportation and accommodation at their own expenses.